Health Care [ 11/12 ] | Pharmaceuticals [ 49/75 ]
NASDAQ | Common Stock
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally.
The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.
It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB PharmaS. A.; F.
Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 8, 24 | -0.25 Increased by +7.41% | -0.20 Decreased by -25.00% |
| May 9, 24 | -0.19 Increased by +40.63% | -0.19 |
| Mar 4, 24 | -0.22 Increased by +31.25% | -0.21 Decreased by -4.76% |
| Nov 7, 23 | -0.24 Increased by +22.58% | -0.20 Decreased by -20.00% |
| Aug 8, 23 | -0.27 Increased by +68.24% | -0.28 Increased by +3.57% |
| May 9, 23 | -0.32 Increased by +34.69% | -0.25 Decreased by -28.00% |
| Feb 28, 23 | -0.32 Increased by +59.49% | -0.45 Increased by +28.89% |
| Nov 3, 22 | -0.31 Increased by +55.71% | -0.45 Increased by +31.11% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 23.49 M Increased by +14.59% | -52.36 M Decreased by -2.43% | Decreased by -222.93% Increased by +10.61% |
| Mar 31, 24 | 21.64 M Increased by +0.21% | -36.80 M Increased by +73.14% | Decreased by -170.07% Increased by +73.20% |
| Dec 31, 23 | 23.89 M Increased by +8.45% | -42.08 M Increased by +29.50% | Decreased by -176.17% Increased by +35.00% |
| Sep 30, 23 | 24.14 M Increased by +2.20% | -45.84 M Increased by +22.37% | Decreased by -189.85% Increased by +24.04% |
| Jun 30, 23 | 20.50 M Decreased by -5.03% | -51.12 M Increased by +67.86% | Decreased by -249.39% Increased by +66.16% |
| Mar 31, 23 | 21.59 M Decreased by -13.00% | -137.02 M Decreased by -51.58% | Decreased by -634.52% Decreased by -74.24% |
| Dec 31, 22 | 22.02 M Decreased by -11.94% | -59.69 M Increased by +59.02% | Decreased by -271.03% Increased by +53.46% |
| Sep 30, 22 | 23.63 M Decreased by -5.20% | -59.05 M Increased by +54.47% | Decreased by -249.94% Increased by +51.98% |